MAO-B-IN-53 

MAO-B-IN-53 is a human monoamine oxidase B (hMAO-B) inhibitor with an IC₅₀ of 0.066 μM. MAO-B-IN-53 exhibits mixed reversible inhibition, binds stably to the hMAO-B active site, and shows high selectivity over hMAO-A. MAO-B-IN-53 acts as a neuroprotective agent, protects against 6-OHDA-induced damage, and exhibits low neurotoxicity in neuroblastoma cells. MAO-B-IN-53 can be used for the research of Parkinson's disease^[1].

MAO-B-IN-53 (Compound 8) (1.25-10 μM; 24 h) exhibits low cytotoxicity against SH-SY5Y cells, with a cell viability of ≥86.5% even at the concentration up to 10 μM after 24 h of incubation^[1].
MAO-B-IN-53 (1.25-5 μM; 25 h) exerts significant neuroprotective effects against 6-OHDA-induced injury in SH-SY5Y cells, with the maximum cell survival rate reaching 70.0% at 1.25 μM^[1].
MAO-B-IN-53 (1.25-2.5 μM; 24 h) exerts in vitro antioxidant activity, at concentrations up to 2.5 μM, it does not increase intracellular ROS levels in SH-SY5Y cells or induce oxidative damage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

327.37

C₂₀H₁₉F₂NO

3069131-62-7

C#CCNC1CCCC2=C1C=CC(OCC3=CC=C(F)C(F)=C3)=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang Z, et al. Discovery of novel N-(prop-2-yn-1-yl)-1,2,3,4-tetrahydronaphthalen-1-amine derivatives as MAO-B inhibitors for the treatment of Parkinson's disease. J Enzyme Inhib Med Chem. 2026;41(1):2606434.  [Content Brief]